6.1.2 ANTIMICROBIAL STEWARDSHIP

ANTIMICROBIAL STEWARDSHIP

Intervention Type	3rd Q 2022	4th Q 2022	1st Q 2023	2nd Q 2023	12 Month Total
De-escalation	306	321	350	359	**1,336**
Dose adjustment	2,705	2,979	3,123	2,991	**11,798**
Bug-Drug mismatch	85	97	121	135	**438**
IV to PO conversion	280	336	488	444	**1,548**
Therapeutic duplication	70	73	138	116	**397**
Totals	**3,446**	**3,806**	**4,220**	4045	15,517

ANTIMICROBIAL STEWARDSHIP

FORMULARY UPDATES	POWERPLANS	QUALITY IMPROVEMENT
Standardization of Restriction Process for Antimicrobials • Ceftaroline, Dalbavancin • Vancomycin oral liquid	**Updated Post-Splenectomy Powerplan**	**Lab Updates** • Improved specificity testing via VITEK ID cards • Updated per CLSI standards for MICs • Optimization of Procalcitonin Laboratory based reporting • Antibiogram Update
Formulary Additions • Bexsero Vaccine, Nitazoxanide • Vancomycin oral capsule **Formulary Removal** • Ciprofloxacin IV/PO, Prevnar-13, Lindane Shampoo	**Implementation of Disease State Specific Powerplans to Align with Joint Commission Standards:** UTI and SSTI	**Interdisciplinary Process Improvement** • Surgical Site Infection Team-Updated Antibiotic Guidance • Trauma-C.diff taskforce
Formulary Streamlining • Pneumococcal Vaccination based on new CDC recommendations • COVID-19 Treatment Criteria	**Updated C.diff Powerplan to Reflect Formulary Update**	**COVID-19 Treatment Consent**